Curis Inc. (CRIS) Given a $7.00 Price Target by RBC Capital Markets Analysts
Curis Inc. (NASDAQ:CRIS) has been given a $7.00 price objective by stock analysts at RBC Capital Markets in a note issued to investors on Wednesday. The firm presently has a a “buy” rating on the stock. RBC Capital Markets’ price target indicates a potential upside of 131.02% from the company’s previous close.
A number of other equities analysts have also commented on CRIS. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research note on Tuesday, October 4th. Robert W. Baird reissued an “outperform” rating and issued a $7.00 price objective on shares of Curis in a research note on Wednesday, September 7th. Finally, FBR & Co reissued a “buy” rating on shares of Curis in a research note on Thursday, September 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Curis currently has an average rating of “Buy” and a consensus price target of $5.05.
Curis (NASDAQ:CRIS) traded down 2.31% on Wednesday, reaching $2.96. The company had a trading volume of 468,557 shares. The company’s 50 day moving average price is $2.26 and its 200-day moving average price is $1.87. Curis has a 12 month low of $1.25 and a 12 month high of $3.42. The company’s market capitalization is $383.24 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/curis-inc-cris-given-a-7-00-price-target-by-rbc-capital-markets-analysts.html
Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. Curis’s quarterly revenue was down 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.06) EPS. On average, equities analysts predict that Curis will post ($0.37) earnings per share for the current fiscal year.
In other news, major shareholder Discovery Technologie Aurigene bought 10,208,333 shares of the company’s stock in a transaction dated Wednesday, September 7th. The stock was bought at an average price of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the transaction, the insider now directly owns 27,328,464 shares in the company, valued at approximately $65,588,313.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.09% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its stake in Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock worth $171,000 after buying an additional 1,418 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Curis by 0.7% in the second quarter. Bank of New York Mellon Corp now owns 357,246 shares of the company’s stock worth $558,000 after buying an additional 2,501 shares during the last quarter. Royal Bank of Canada increased its stake in Curis by 0.9% in the second quarter. Royal Bank of Canada now owns 811,129 shares of the company’s stock worth $1,265,000 after buying an additional 7,220 shares during the last quarter. Geode Capital Management LLC increased its stake in Curis by 2.5% in the first quarter. Geode Capital Management LLC now owns 772,054 shares of the company’s stock worth $1,243,000 after buying an additional 18,476 shares during the last quarter. Finally, Teachers Advisors Inc. increased its stake in Curis by 11.5% in the second quarter. Teachers Advisors Inc. now owns 180,776 shares of the company’s stock worth $282,000 after buying an additional 18,634 shares during the last quarter. Institutional investors own 52.36% of the company’s stock.
Curis Company Profile
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.